Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Google Secures Pentagon AI Deal for Classified Projects 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
IRVINE, Calif., Feb. 08, 2016 -- CombiMatrix Corporation (NASDAQ:CBMX) announces that it will release financial results for the three months and full year ended December 31, 2015 after market close on Wednesday, February 17, 2016. CombiMatrix management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.
| Live Call: | U.S. | (866) 634-2258 |
| International: | (330) 863-3454 | |
| Live Webcast: | http://investor.combimatrix.com/events.cfm | |
| The webcast replay will be archived for 30 days | ||
| Replay: | U.S. | (855) 859-2056 |
| International: | (404) 537-3406 | |
| Passcode: | 42555328 | |
| The telephone replay will be available for seven days | ||
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in prenatal diagnostics, miscarriage analysis for recurrent pregnancy loss, pediatric genetics and pre-implantation genetic screening, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization (FISH) and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making. Additional information about CombiMatrix is available at www.combimatrix.com or by calling (800) 710-0624.
Company Contact: Mark McDonough President & CEO, CombiMatrix Corporation (949) 753-0624 Investor Contact: LHA Jody Cain (310) 691-7100 [email protected]
